Sanofi Presents Results of Dupixent (dupilumab) in P-III Trial for the Treatment of Atopic Dermatitis at RAD 2021
Shots:
- The P-III trial evaluates Dupixent + SoC low-potency TCS vs TCS alone (PBO) in 162 children aged 6mos. to 5yrs. with AD. The therapy is being developed in collaboration with Regeneron
- The trial met all 1EPs & 2EPs i.e., @16wks, patients achieved clear or almost clear skin (28% vs 4%), ≥75% improvement in overall disease severity (53% vs 11%), an improvement in itch & EASI (49% vs 2%) & (70% vs 20%) & the safety profile was consistent with the safety profile of Dupixent
- The company is planning for regulatory submission in the US at the end of 2021 & EU in H1’22. The therapy is approved in the US, EU, Japan & other countries globally for AD & asthma or CRSwNP in different age populations
Ref: Globe Newswire | Image: Sanofi
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com